HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives

Table 6 Current approved drugs and NCCN 2022 recommended drugs for patients with advanced/metastatic GC

Drug	Population	Treatment Setting	Approved/Time	NCCN2022 Recommendation
Trastuzumab	HER2-positive metastatic GC	First-line	FDA/2010.10 NMPA/2012.08	First-line therapy for patients with HER2-positive advanced/metastatic GC
Disitamab vedotin	HER2-overexpressing (IHC 2+/3+) advanced/metastatic G/GEJ adenocarcinoma	Second-line and beyond	NMPA/2021.06	/
Pembrolizumab	HER2-positive locally advanced unresectable/metastatic G/GEJ adenocarcinoma (PD-L1 CPS ≥ 1)	First-line	FDA/2021.5	First-line therapy for patients with HER2-positive locally advanced/metastatic G/GEJ adenocarcinoma Second-line and beyond for dMMR, MSI-H or TMB-H tumors
DS8201	HER2-positive locally advanced/metastatic G/GEJ adenocarcinoma	Second-line and beyond	FDA/2021.01	Second-line and beyond for patients with HER2-positive locally advanced/metastatic G/GEJ adenocarcinoma
Nivolumab	Advanced/metastatic G/GEJ adenocarcinoma	First-line	FDA/2021.04 NMPA/2021.08	HER2-first-line therapy for patients with advanced/metastatic GC
Apatinib	HER2-positive Advanced G/GEJ adenocarcinoma	Third-line	NMPA/2014.12	/

Abbreviations: GC gastric cancer, G/GEJ gastric/gastroesophageal junction, PD-L1 programmed cell death-ligand 1, CPS combined positive score, FDA the U.S. Food and Drug Administration, NMPA national medical products administration, dMMR mismatch repair-deficient, MSI-H high microsatellite instability, TMB-H high tumor mutational burden

ISSN: 2050-7771